WHO Priority Pathogens List paper is published; Industry action report to be released

Dear All:

First, the methods behind the WHO Priority Pathogens List (PPL, released on 25 Feb 2017) have now been published by Tacconelli et al. in Lancet Infectious Diseases along with an editorial by Tillottson. As further context while you review these excellent papers, you might also find it helpful to have to hand this slide deck comparing the WHO PPL, the 2013 CDC threat list, and the 2008-9 ESKAPE pathogen list. (11 Feb 2020 addendum: I have updated that deck to also show the CDC 2019 threat list. Get the new deck here, go here for a newsletter about CDC’s update, and go here for a discussion of the problem of setting antibiotic R&D priorities.)

You should read the papers yourself, but the quick summary is that the authors used multicriteria decision analysis across 10 axes (mortality, health-care burden, community burden, prevalence of resistance, 10-year trend of resistance, transmissibility, preventability in the community setting, preventability in the health-care setting, treatability, and pipeline) to prioritize the pathogens. Very importantly, they obtained input from 70 experts spanning all 6 WHO regions, thus ensuring a broad view on global needs.

Second, there has been a lot of action underway to address the gaps identified by the WHO PPL and the related WHO pipeline review from this past summer. I am seeing significant amounts of company-level activity and one measure of this is that CARB-X now lists 22 projects in its portfolio page. As an additional perspective on recent actions at the Industry level, I’ve learned that the AMR Industry Alliance will release its first Global Progress report on 18 Jan 2018 in Geneva. You can register to attend that meeting via this link. This is all very exciting to see!

In closing, all best wishes for the holidays and thank you for being one of the just over 1,000 subscribers to this newsletter! I’ve enjoyed writing these occasional updates and I’ve also appreciated all the helpful comments and tips that I’ve received. 

Ho, ho, ho! –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Fireside Chat with BARDA’s Branch Chief for Antimicrobials

Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and

Japan Pulls for Pandemic Preparedness: Nikkei FT Conference

Dear All, As we discussed in the 5 Nov 2023 “Pulling for Pandemic Preparedness” newsletter, AMR is a global threat: resistance in one part of the world can suddenly appear in your hospital. As an example of that sort of threat, Jason Gale’s 30 Oct 2023 newsletter entitled “Untreatable Typhoid Should Make You Worry About Poop”

Pulling for Pandemic Preparedness

Dear All, This evening I’d like to bring together several relatively recent reports and note how all of them focus in one way or another on Pulling for Pandemic Preparedness … perhaps we can call this the Rule of 3 Ps. And as an aside, I’ll note that I learned the Rule of 4 Ps

PACE: A new £30m fund for AMR innovation

Dear All, Exciting additional news merits two newsletters in one day! I’ll keep it brief and quote directly from the website: “Innovate UK, LifeArc, and Medicines Discovery Catapult (MDC) have joined forces to create PACE (Pathways to Antimicrobial Clinical Efficacy), a £30 million initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. PACE has today (19 October 2023) announced

Scroll to Top